Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Angiotensin II vs Norepinephrine for AKI Prevention in Cardiac Surgery
NCT06615102Phase 3Recruiting
- Sponsor
- Universität Münster
- Start
- Mar 2025
- Primary completion
- Jan 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of Angiotensin II in Vasoplegia and hypotension (2 arms), sponsored by Universität Münster. Primary endpoint: Rate of AKI KDIGO stage 2 or 3 or death at 72 hours. Started Mar 2025; status: recruiting.
02
Drugs
Angiotensin II
03
Conditions
Vasoplegiahypotension
Beyond the preview
Go deeper on NCT06615102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06615102.